The effect of bariatric surgery on the pharmacokinetics of venlafaxine
Withdrawn
- Conditions
- bariatrische chirurgieBariatric surgerydepression10027946
- Registration Number
- NL-OMON47961
- Lead Sponsor
- Maasstadziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 12
Inclusion Criteria
The participant is on the waiting list for gastric bypass surgery and is using
oral venlafaxine without changes in dosages for the past four weeks.
Exclusion Criteria
Persons who have previously undergone bariatric surgery.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>AUC corrected for the dose</p><br>
- Secondary Outcome Measures
Name Time Method <p>Cmax, Tmax and T1/2.</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does bariatric surgery alter venlafaxine metabolism in patients with depression?
What biomarkers correlate with venlafaxine pharmacokinetic changes post-sleeve gastrectomy?
Do CYP2D6 polymorphisms influence venlafaxine efficacy after Roux-en-Y gastric bypass?
What adverse events are associated with venlafaxine use in post-bariatric surgery patients?
How does venlafaxine compare to SSRIs in managing depression after bariatric procedures?